title: Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.|University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Tam
authors.affiliation: Neurology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.|University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: Thomas
authors.initials: T
authors.lastname: Kimber
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.|University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010880:Piperidines; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: BTK inhibition; chemotherapy; leptomeningeal; lymphoma; targeted therapy